Öppna denna publikation i ny flik eller fönster >>Visa övriga...
2021 (Engelska)Ingår i: Molecular Pharmaceutics, ISSN 1543-8384, E-ISSN 1543-8392, Vol. 18, nr 12, s. 4428-4436Artikel i tidskrift (Refereegranskat) Published
Abstract [en]
Type 1 diabetes develops in childhood and adolescence, with peak incidence in the early teenage years. There is an urgent need for an accurate method to detect insulin-producing β-cells in patients that is not affected by alterations in β-cell function. As part of our research program to design specific probes to measure β-cell mass, we recently developed a novel insulin-binding peptide probe (IBPP) for the detection of β-cells in vivo. Here, we applied our innovative method to show specific labeling of this IBPP to human and mouse fixed β-cells in pancreatic islets. Importantly, we showed staining of human and mouse islets in culture without any negative functional or cell viability impact. Moreover, the IBPP-stained mouse islets after tail vein injection in vivo, albeit with batch differences in staining efficiency. In conclusion, we provide evidence showing that the IBPP can be used for future accurate detection of β-cell mass in a variety of preclinical models of diabetes.
Ort, förlag, år, upplaga, sidor
American Chemical Society (ACS), 2021
Nyckelord
glucose-stimulated insulin secretion, insulin-binding peptide, pancreatic islets, type 1 diabetes, β-cell imaging
Nationell ämneskategori
Endokrinologi och diabetes Cell- och molekylärbiologi
Identifikatorer
urn:nbn:se:umu:diva-189219 (URN)10.1021/acs.molpharmaceut.1c00616 (DOI)000755047200018 ()2-s2.0-85118183928 (Scopus ID)
Forskningsfinansiär
EU, FP7, Sjunde ramprogrammet, 289932VetenskapsrådetNovo Nordisk
2021-11-102021-11-102023-09-05Bibliografiskt granskad